Brevan Howard Capital Management’s Protagonist Therapeutics PTGX Stock Holding History

Brevan Howard Capital Management’s Portfolio PTGX Stock Details PTGX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$3.1M	Buy	+25,270	New	+$2.64M	0.02%	533
2025 Q4	–	Sell	-7,598	Closed	-$505K	–	2187
2025 Q3	$505K	Sell	7,598 -19,396	-72%	-$1.1M	﹤0.01%	1290
2025 Q2	$1.49M	Buy	26,994 +10,880	+68%	+$522K	0.01%	869
2025 Q1	$779K	Buy	+16,114	New	+$675K	0.01%	587
2024 Q3	–	Sell	-8,971	Closed	-$311K	–	1376
2024 Q2	$311K	Buy	+8,971	New	+$263K	﹤0.01%	764
2024 Q1	–	Sell	-11,806	Closed	-$271K	–	1288
2023 Q4	$271K	Buy	+11,806	New	+$207K	﹤0.01%	764

Other funds holding PTGX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Johnson & Johnson New Brunswick, New Jersey $799M AUM 253.51% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Brevan Howard Capital Management's PTGX Position: Q2 2026 in Review

Brevan Howard Capital Management opened a new position in Protagonist Therapeutics (PTGX) in Q2 2026: 25,270 shares worth $3.1M. The stake represents 0.02% of the portfolio and ranks #533 among its holdings. This is a return to the name: Brevan Howard Capital Management previously reported a position in PTGX as recently as Q3 2025.

Brevan Howard Capital Management first reported a position in PTGX in Q4 2023 and has held it in 6 quarters since. 343 funds tracked by Wall St. Rank hold PTGX as of Q2 2026.

Brevan Howard Capital Management held 25,270 shares of Protagonist Therapeutics worth $3.1M as of Q2 2026.
Protagonist Therapeutics was a new Brevan Howard Capital Management position in Q2 2026.
Protagonist Therapeutics made up 0.02% of Brevan Howard Capital Management's portfolio in Q2 2026, its #533 holding.
Brevan Howard Capital Management first reported a position in Protagonist Therapeutics in Q4 2023 and has held it in 6 quarters since.
343 funds tracked by Wall St. Rank held Protagonist Therapeutics as of Q2 2026.

Based on Brevan Howard Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.